Nodelman Oleg's Form 4 filing
Nuvation Bio Inc. (NUVB) · filed Nov 30, 2021
- Accession no.
- 0001567619-21-021329
- Filed
- Nov 30, 2021, 6:07 PM ET
- Trade date
- Mar 31-Nov 24, 2021
- Filing delay
- 244 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market purchases total $3.49M. Open-market sales total $2.07M. It was filed 244 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nodelman OlegCIK 0001454385 | Director |
| EcoR1 Capital Fund, L.P.CIK 0001567938 | Other: Affiliate of Director |
| EcoR1 Capital, LLCCIK 0001587114 | Other: Affiliate of Director |
| EcoR1 Capital Fund Qualified, L.P.CIK 0001598292 | Other: Affiliate of Director |
| EcoR1 Venture Opportunity Fund, LPCIK 0001778011 | Other: Affiliate of Director |
| Biotech Opportunity GP, LLCCIK 0001816370 | Other: Affiliate of Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2021 | Class A Common Stock | PPurchaseAcquired | +151,544 | $10.45 | +$1,583,634.8 | 6,735,790 | Indirect | |
| Mar 31, 2021 | Class A Common Stock | SSaleAcquired | +151,544 | $10.45 | +$1,583,634.8 | 1,145,600 | Indirect | |
| Jul 31, 2021 | Class A Common Stock | PPurchaseAcquired | +56,598 | $8.64 | +$489,006.72 | 7,198,407 | Indirect | |
| Jul 31, 2021 | Class A Common Stock | SSaleDisposed | −56,598 | $8.64 | −$489,006.72 | 1,147,483 | Indirect | |
| Nov 24, 2021 | Class A Common Stock | PPurchaseAcquired | +163,268 | $7.69 | +$1,254,861.52 | 7,361,675 | Indirect | |
| Nov 24, 2021 | Class A Common Stock | PPurchaseAcquired | +21,758 | $7.69 | +$167,229.81 | 1,169,241 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
The Reporting Persons are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Mr. Nodelman serves on the board of directors of the issuer.